Quarterly report pursuant to Section 13 or 15(d)

Business (Details)

v3.19.3
Business (Details)
3 Months Ended 9 Months Ended
Nov. 01, 2019
USD ($)
Mar. 08, 2019
$ / shares
shares
Sep. 30, 2019
USD ($)
$ / shares
shares
Mar. 31, 2019
USD ($)
$ / shares
shares
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
product
$ / shares
Sep. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Subsequent Event [Line Items]                
Net loss     $ (4,016,454)   $ (24,603,575) $ (17,693,601) $ (34,493,895)  
Net cash used in operating activities           (17,453,929) (1,152,446)  
Accumulated deficit     (115,911,671)     (115,911,671)   $ (98,218,070)
Cash and cash equivalents     $ 5,250,651   $ 6,838,353 $ 5,250,651 $ 6,838,353 $ 10,646,301
Sale of stock (in shares) | shares   363,637            
Purchase price (in dollars per share) | $ / shares   $ 5.50            
Neurological Clinical And Preclinical Stage Compounds                
Subsequent Event [Line Items]                
Number of products in development | product           3    
Preclinical Pediatric Orphan Rare Disease Compound                
Subsequent Event [Line Items]                
Number of products in development | product           1    
Millipred                
Subsequent Event [Line Items]                
Number of marketed products | product           1    
Underwritten Public Offering | Common stock                
Subsequent Event [Line Items]                
Sale of stock (in shares) | shares       1,818,182        
Purchase price (in dollars per share) | $ / shares       $ 5.50        
Net proceeds       $ 9,000,000        
Armistice Purchase Agreement                
Subsequent Event [Line Items]                
Sale of stock (in shares) | shares     1,200,000          
Purchase price (in dollars per share) | $ / shares     $ 3.132     $ 3.132    
Net proceeds     $ 3,700,000          
Armistice | Underwritten Public Offering | Common stock                
Subsequent Event [Line Items]                
Sale of stock (in shares) | shares       363,637        
Pediatric Portfolio | Subsequent Event                
Subsequent Event [Line Items]                
Consideration $ 17,000,000              
Proceeds from sale of assets 4,500,000              
Assumption of debt on sale of assets 15,000,000              
Pediatric Portfolio | Subsequent Event | AYTU BioScience, Inc                
Subsequent Event [Line Items]                
Convertible preferred stock received 12,500,000              
Liabilities assumed by buyer $ 11,000,000